Literature DB >> 23356974

Target of prophylaxis in severe haemophilia: more than factor levels.

Antonio Coppola, Massimo Franchini.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23356974      PMCID： PMC3729119          DOI： 10.2450/2012.0244-12

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  26 in total

1.  Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management).

Authors:  S Donadel-Claeyssens
Journal:  Haemophilia       Date:  2006-03       Impact factor: 4.287

2.  Long-term outcome of individualized prophylactic treatment of children with severe haemophilia.

Authors:  H M van den Berg; K Fischer; E P Mauser-Bunschoten; F J Beek; G Roosendaal; J G van der Bom; H K Nieuwenhuis
Journal:  Br J Haematol       Date:  2001-03       Impact factor: 6.998

3.  Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study.

Authors:  B M Feldman; M Pai; G E Rivard; S Israels; M-C Poon; C Demers; S Robinson; K-H Luke; J K M Wu; K Gill; D Lillicrap; P Babyn; M McLimont; V S Blanchette
Journal:  J Thromb Haemost       Date:  2006-06       Impact factor: 5.824

4.  Haemophilia in Sweden. III. Symptomatology, with special reference to differences between haemophilia A and B.

Authors:  O RAMGREN
Journal:  Acta Med Scand       Date:  1962-02

Review 5.  Modern treatment of haemophilia.

Authors:  E Berntorp; V Boulyjenkov; D Brettler; M Chandy; P Jones; C Lee; J Lusher; P Mannucci; I Peak; K Rickard
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

6.  Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B.

Authors:  A Ahlberg
Journal:  Acta Orthop Scand Suppl       Date:  1965

7.  A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group.

Authors:  L M Aledort; R H Haschmeyer; H Pettersson
Journal:  J Intern Med       Date:  1994-10       Impact factor: 8.989

8.  Validation of a composite score for clinical severity of hemophilia.

Authors:  S Schulman; A Eelde; M Holmström; G Ståhlberg; J Odeberg; M Blombäck
Journal:  J Thromb Haemost       Date:  2008-07-01       Impact factor: 5.824

9.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

Authors:  Marilyn J Manco-Johnson; Thomas C Abshire; Amy D Shapiro; Brenda Riske; Michele R Hacker; Ray Kilcoyne; J David Ingram; Michael L Manco-Johnson; Sharon Funk; Linda Jacobson; Leonard A Valentino; W Keith Hoots; George R Buchanan; Donna DiMichele; Michael Recht; Deborah Brown; Cindy Leissinger; Shirley Bleak; Alan Cohen; Prasad Mathew; Alison Matsunaga; Desiree Medeiros; Diane Nugent; Gregory A Thomas; Alexis A Thompson; Kevin McRedmond; J Michael Soucie; Harlan Austin; Bruce L Evatt
Journal:  N Engl J Med       Date:  2007-08-09       Impact factor: 91.245

10.  Clinical outcome of moderate haemophilia compared with severe and mild haemophilia.

Authors:  I E M den Uijl; K Fischer; J G Van Der Bom; D E Grobbee; F R Rosendaal; I Plug
Journal:  Haemophilia       Date:  2008-08-16       Impact factor: 4.287
View more
  3 in total

Review 1.  Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia.

Authors:  Albert Farrugia; Giancarlo M Liumbruno; Fabio Candura; Samantha Profili; Josephine Cassar
Journal:  Blood Transfus       Date:  2018-09-03       Impact factor: 3.443

2.  Monitoring of different factor VIII replacement products using a factor VIII one-stage clotting assay on cobas t 511/711 analysers.

Authors:  Carolin Ketteler; Ingrid Hoffmann; Simon Davidson; Andreas Tiede; Nina Richter
Journal:  Haemophilia       Date:  2021-09-30       Impact factor: 4.263

3.  Treatment with radiosynoviorthesis in hemophilic patients with and without inhibitor.

Authors:  Mario Edgar Tena-Sanabria; Yoriko Fabiola Rojas-Sato; José Carlos Castañeda-Resendiz; Gabriela Fuentes-Herrera; Félix Alejandro Álvarez-Martínez; Yureni Iraí Tena-Gonzalez; Juan Carlos Núñez-Enríquez
Journal:  BMC Pediatr       Date:  2020-04-20       Impact factor: 2.125
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.